Trial Profile
A phase I, randomized, double-blind, placebo-controlled study of combination therapy doublet, PTI-808 and PTI-801
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Dirocaftor (Primary) ; Posenacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kineta; Proteostasis Therapeutics; Yumanity Therapeutics
- 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
- 17 Oct 2018 According to a Proteostasis Therapeutics media release, The fourth and highest dose cohort, patients receiving PTI-801 (400 mg) and PTI-808 (300 mg), is ongoing, with data expected in the first quarter of 2019.
- 17 Oct 2018 Preliminary results (n=21) presented in a Proteostasis Therapeutics media release.